Back to search
FDAFDA · Food and drugs·Recall number D-1253-2014

Tikosyn® (dofetilide) 500 mcg (0.5mg) capsules, 60-count bottle, Rx only Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, NDC 00069-5820-60

Published April 30, 2014 · Recall initiated: April 8, 2014

Summary

FDA records drug Class II recall D-1253-2014, published April 30, 2014 and initiated April 8, 2014. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 23,064 bottles; Lot: H48496, H48497; Exp 05/15. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foriegn Tablets/Capsules: A single Tikosyn® (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn® (dofetilide) 500 mcg (0.5 mg).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
US Nationwide including Puerto Rico and US Virgin Islands. 65 federal government accounts received the affected product directly from Pfizer Inc
Lot
H48496, H48497; Exp 05/15
Risk classification
Class II
Area (FDA)
drug
Country
US

Related recalls

Questions about this recall

Was Tikosyn® (dofetilide) 500 mcg (0.5mg) capsules, 60-count bottle, Rx only Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, NDC 00069-5820-60 recalled?

Yes. FDA published recall D-1253-2014 on April 30, 2014. Reported hazard: Presence of Foriegn Tablets/Capsules: A single Tikosyn® (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn® (dofetilide) 500 mcg (0.5 mg).

What should I do if I have this product?

Voluntary: Firm initiated · Letter